Switzerland-based Roche's lung cancer drug Tecentriq (atezolizumab) has improved overall survival rate in a phase III IMpower110 study, it was reported yesterday.
The trial is assessing the product as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations (Wild-Type or WT).
The company's phase III trial achieved its primary endpoint in an interim analysis demonstrating that Tecentriq monotherapy had a statistically significant overall survival benefit in people with high PD-L1 expression (TC3/IC3-WT) compared against chemotherapy alone.
The firm will share the positive data with global health authorities such as the US Food and Drug Administration and European Medicines Agency to offer the new drug option to patients.
The product is a monoclonal antibody developed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. It will allow the activation of T cells by inhibiting PD-L1.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review